At a glance
ClinicalIndex Comparison Record- ✓Age 21 to 75 years
- ✓Acute myocardial infarction with total or sub-total coronary occlusion documented on angiography
- ✓Successful percutaneous revascularization with restoration of TIMI grade 3 coronary flow
- ✓Current treatment with aspirin and a thienopyridine (clopidogrel or ticlopidine)
- ✕Hemodynamic instability, cardiogenic shock, or severe congestive heart failure
- ✕Time from symptom onset to revascularization procedure exceeding 16 hours
- ✕Prior treatment with intravenous thrombolytic agents for acute myocardial infarction
- ✕Anticipated need for additional revascularization procedures
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction
In Brief
A Phase 2 clinical trial evaluating Recombinant human erythropoietin alfa (drug) and Placebo for Myocardial Infarction. Completed, enrolled 44 participants across 1 site.
Detailed Summary
The purpose of this study is to see if a naturally-occurring hormone called erythropoietin changes the action of platelets in the blood. Patients with heart attacks are treated with medicines to reduce the clotting action of platelets. This study is trying to determine whether erythropoietin alters the clotting action of platelets in patients receiving anti-platelet medicines. It is important to understand the effects of erythropoietin on platelets since preliminary studies in animals suggest that erythropoietin may protect the heart from damage during a heart attack.
Study Details
Timeline
Interventions
200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days
Normal saline to match active drug (rHuEpo)